Exchange Session 1 – Explore
April 4, 2024
3:00 pm
4:00 pm
Debra Newman, PA-C, MPAS, MPH; Kristin Wason, NP-C, CARN; and Brian Fuehrlein, MD

Review medications for opioid use disorders (MOUD), with a focus on buprenorphine treatment and its various formulations, and strategies for including harm reduction approaches into care. Discuss administrative, clinical and financial considerations, and provide resources for both prescribers and non-prescribers.

Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior

Cost: No fee

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, licensed counselors, social workers, clinical administrators, and healthcare teams.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, and Interprofessional Continuing Education (IPCE) credit. Note: A Certificate of Attendance which acknowledges 1 hour of participation is also available (0 CE).

Webinar Description: Have you considered treating patients with opioid use disorder (OUD) using Medications for Opioid Use Disorder (MOUD)? Have you wondered what is required to prescribe buprenorphine or other pharmacotherapies? If you answered yes to either or both of these questions, this PCSS-MOUD Exchange session could provide you with the critical information and steps in determining the readiness of your site and clinical leadership. Initiating Medications for Opioid Use Disorder (MOUD) into your setting requires that you understand how pharmacotherapies work, including buprenorphine and its various formulations.

Educational Objectives:

  • Identify the three FDA-approved medications to treat OUD and describe the specific formulations of buprenorphine
  • Understand how each medication works, what side-effects may exist, and how prescribers/patients make decisions about which to choose
  • Review the risks of opioid overdose and role of Naloxone
  • Identify next steps (i.e., financial and clinical) to guide implementation of MOUD
  • Identify resources targeted to both prescribing (e.g., MD, DO, NP, PA, etc.) and non-prescribing (e.g., counselors, social workers, clinic administrators, etc.) healthcare team members

Accreditation Statement:
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements:

American Academy of Addiction Psychiatry designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners
American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 CNE credits.

AAPA Category 1 CME

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other Health Professionals and Other Learners
Participants will receive a certificate stating this program is designated for 1 AMA PRA Category 1 Credits™. This credit is accepted by the AANP and the AAPA.

IPCE Credit

All Learners
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education credits for learning and c

American Academy of Addiction Psychiatry